Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall?
Syndax Pharmaceuticals (NASDAQ:SNDX) reported Q2 revenue of about $115 million, nearly doubling year over year, with Revuforj at $55 million (+91% YoY) and Niktimvo at $60 million (+67% YoY). Despite the growth, shares fell 2.41%. Management cited patient-start variability and ongoing profitability constraints, while pending Q4 data and pipeline updates remain key.
How this was made
The 30-second read
Why it matters
The article frames the selloff as a mismatch between top-line growth and investor concerns about competitive dynamics, profitability timeline, and pending Q4 clinical catalysts.
Market read
Traders are likely to focus on whether Revuforj patient-start variability is transient versus the start of competitive pressure, with Q4 data as the next major decision point.
What to watch
Niktimvo’s economics are partially obscured by partner revenue recognition (only 25% to 30% booked), so reported collaboration revenue may understate the eventual margin inflection if scaling accelerates.
Background
Syndax’s Q2 results showed rapid growth in Revuforj and Niktimvo, alongside a strengthened cash position and additional pipeline candidates.
Ticker impact
Syndax reported Q2 combined product sales of $115M and annualizing above $200M, but the stock fell 2.41% as investors weighed competitive and margin risks.
Choppy near-term trading likely as investors wait for pending Q4 data (axatilimab IPF and frontline cGVHD, plus NUP98 leukemia) to validate durability and competitive trajectory.
The article’s decision-relevant items are the post-earnings selloff explanation and forward-looking uncertainty (competition effects, collaboration revenue recognition, pending catalysts), not a new guidance change or fresh datapoint beyond the quarter itself.
Market effects
Highlights how investors in oncology rare-disease names may discount revenue growth when patient starts show variability and profitability timing remains distant.
None material beyond US small/mid-cap biotech sentiment.
Limited; story is company-specific with no clear cross-border regulatory or supply-chain shock.
Counterpoint
The durability metrics (resumption after transplant and 1-year persistence) could outweigh early patient-start fluctuations, implying the market may be overreacting to short-term competitive noise.
Key entities
- companySyndax Pharmaceuticals
NASDAQ-listed biotech whose Q2 revenue nearly doubled but shares fell after investors focused on competitive and profitability details.
- productRevuforj
One of Syndax’s two approved drugs; Q2 net revenue $55M, up 91% YoY, with durability metrics discussed.
- productNiktimvo
Second approved drug; Q2 revenue $60M, up 67% YoY, with partner accounting affecting reported economics.
- partnerIncyte
Partner whose reported Niktimvo sales are only partially recognized by Syndax as collaboration revenue.
